CD274 and breast carcinoma: Particular characteristics that have been predictive of immunotherapy benefit in TNBC include a high level of programmed cell death ligand 1 (PD-L1) expression and more tumour infiltration lymphocytes (TILs) in contrast to other breast cancer subtypes.